Literature DB >> 10852707

Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA.

E Ballestar1, T M Yusufzai, A P Wolffe.   

Abstract

We have investigated the properties of mutant forms of the methyl-CpG binding transcriptional repressor MeCP2 associated with Rett syndrome, a childhood neurodevelopmental disorder. We find that four Rett syndrome mutations at known sites within the methyl-CpG binding domain (MBD) impair binding to methylated DNA, but have little effect on nonspecific interactions with unmethylated DNA. Three of these mutations (R106W, R133C, and F155S) have their binding affinities for methylated DNA reduced more than 100-fold; this is consistent with the hypothesis that impaired selectivity for methylated DNA of mutant MeCP2 contributes to Rett syndrome. However, a fourth mutant, T158M, has its binding affinity for methylated DNA reduced only 2-fold, indicative either of additional distinct regulatory functions associated with the MBD or of an exquisite sensitivity of developing neurons to the selective association of MeCP2 with methylated DNA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852707     DOI: 10.1021/bi0001271

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  57 in total

Review 1.  Rett syndrome and the MECP2 gene.

Authors:  T Webb; F Latif
Journal:  J Med Genet       Date:  2001-04       Impact factor: 6.318

2.  Functional consequences of Rett syndrome mutations on human MeCP2.

Authors:  T M Yusufzai; A P Wolffe
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

Review 3.  Above and within the genome: epigenetics past and present.

Authors:  F D Urnov; A P Wolffe
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-04       Impact factor: 2.673

4.  Methylation-dependent silencing at the H19 imprinting control region by MeCP2.

Authors:  Robert A Drewell; Carolyn J Goddard; Jean O Thomas; M Azim Surani
Journal:  Nucleic Acids Res       Date:  2002-03-01       Impact factor: 16.971

Review 5.  Rett syndrome and MeCP2: linking epigenetics and neuronal function.

Authors:  Mona D Shahbazian; Huda Y Zoghbi
Journal:  Am J Hum Genet       Date:  2002-11-19       Impact factor: 11.025

6.  Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin.

Authors:  Tatiana Nikitina; Xi Shi; Rajarshi P Ghosh; Rachel A Horowitz-Scherer; Jeffrey C Hansen; Christopher L Woodcock
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

7.  Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.

Authors:  Christopher A Chapleau; Gaston D Calfa; Meredith C Lane; Asher J Albertson; Jennifer L Larimore; Shinichi Kudo; Dawna L Armstrong; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-05-12       Impact factor: 5.996

Review 8.  Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission.

Authors:  Lisa M Monteggia; Ege T Kavalali
Journal:  Biol Psychiatry       Date:  2008-12-05       Impact factor: 13.382

9.  Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain.

Authors:  S Kudo; Y Nomura; M Segawa; N Fujita; M Nakao; C Schanen; M Tamura
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

10.  A novel hypomorphic MECP2 point mutation is associated with a neuropsychiatric phenotype.

Authors:  Abidemi A Adegbola; Michael L Gonzales; Andrew Chess; Janine M LaSalle; Gerald F Cox
Journal:  Hum Genet       Date:  2008-11-07       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.